GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (NAS:POAI) » Definitions » 5-Year Yield-on-Cost %

Predictive Oncology (Predictive Oncology) 5-Year Yield-on-Cost % : 0.00 (As of May. 01, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Predictive Oncology 5-Year Yield-on-Cost %?

Predictive Oncology's yield on cost for the quarter that ended in Dec. 2023 was 0.00.


The historical rank and industry rank for Predictive Oncology's 5-Year Yield-on-Cost % or its related term are showing as below:



POAI's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.2
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Predictive Oncology's 5-Year Yield-on-Cost %

For the Medical Instruments & Supplies subindustry, Predictive Oncology's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Predictive Oncology's 5-Year Yield-on-Cost % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Predictive Oncology's 5-Year Yield-on-Cost % falls into.



Predictive Oncology 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Predictive Oncology is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Predictive Oncology  (NAS:POAI) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Predictive Oncology 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Predictive Oncology (Predictive Oncology) Business Description

Traded in Other Exchanges
N/A
Address
2915 Commers Drive, Suite 900, Eagan, MN, USA, 55121
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.
Executives
Robert L Myers officer: CHIEF FINANCIAL OFFICER 4765 BEACON HILL ROAD, EAGAN MN 55122
Nuzum Charles Lee Sr director 633 1ST STREET WEST, SONOMA CA 95476
Veena Rao director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Matthew Hawryluk director C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
St. Clair Gregory Sr director 1645 WHITLEY DRIVE, HARRISBURG PA 17111
Nancy Chung-welch director P O BOX 1572, PEPPERELL MA 01463
Pamela Bush officer: Chief Business Officer 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Daniel E Handley director 1142 S. DIAMOND BAR BLVD. #464, DIAMOND BAR CA 91765
Raymond F Vennare director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
David Stewart Smith director 151 WASHINGTON STREET, PITTSBURGH PA 15218
J Melville Engle director 1 REMINGTON COURT, NAPA CA 94558
Jenkins Christina Lee Md director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Carl I. Schwartz 10 percent owner 20155 N.E. 38TH COURT, UNIT 3104, AVENTURA FL 33180
Richard L Gabriel director 900 COCOANUT AVENUE, SARASOTA FL 34236
Pamela S Prior director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121

Predictive Oncology (Predictive Oncology) Headlines

From GuruFocus

Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer

By Stock market mentor Stock market mentor 02-03-2023